Dr. Miver Erem Tokuş
NeurosurgeryVerified
- 24+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Neurology Treatments
Ocrevus (ocrelizumab) therapy
What Ocrevus (ocrelizumab) therapy is, how this humanised monoclonal antibody targets CD20-positive B cells in multiple sclerosis, clinical evidence across relapsing and primary progressive forms, infusion schedules, side-effect profiles, approximate treatment costs in Turkey compared with the UK, US and Germany, and what to ask your neurologist before arranging hospital treatment abroad.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Neurology Treatments
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Ocrevus (Ocrelizumab) Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is Ocrevus (ocrelizumab) therapy and how does it work?
Ocrevus (ocrelizumab) therapy is an advanced disease-modifying treatment for adults with active relapsing forms of multiple sclerosis (RMS) or early primary progressive multiple sclerosis (PPMS). As a humanised monoclonal antibody, ocrelizumab selectively binds to the CD20 antigen expressed on pre-B cells and mature B lymphocytes. Once bound, it depletes circulating CD20-positive B cells via antibody-dependent cellular cytotoxicity and complement lysis, while sparing stem cells and plasma cells so baseline immunoglobulin production continues.
By clearing inflammatory B cells, the treatment halts the autoimmune cascade that damages myelin sheaths around central nervous system nerve fibres. Many international patients travel abroad to access hospital infusion suites with transparent private pricing. For comprehensive hospital care options, explore our guide to neurosurgery treatments in Turkey (hub).
How is the intravenous infusion administered step by step?
Administering ocrelizumab follows a strict clinical protocol within an accredited hospital infusion suite. Because the drug can cause acute infusion reactions, the initial cycle is split into two separate 300 mg infusions given two weeks apart. Subsequent maintenance doses are delivered as a single 600 mg infusion every six months.
The hospital administration procedure follows four structured stages:
- Pre-infusion screening: Full blood counts, liver enzymes, and quantitative immunoglobulin levels (IgG, IgM, IgA) are assessed. Screening confirms negative status for active hepatitis B and tuberculosis.
- Premedication: Thirty to sixty minutes prior to infusion, the medical team administers intravenous methylprednisolone, an antihistamine, and paracetamol to reduce histamine-mediated reactions.
- Intravenous infusion: Diluted in saline, the drug is infused using an automated pump. The infusion rate starts slowly and increases every 30 minutes, taking two to three and a half hours.
- Post-infusion observation: Patients remain under clinical monitoring for at least one hour post-infusion to check blood pressure, heart rate, and skin condition before discharge.
Does Ocrevus (ocrelizumab) therapy work for relapsing and progressive MS?
Extensive clinical trial data demonstrates that ocrelizumab provides robust disease suppression. In the Phase III OPERA I and OPERA II trials for relapsing multiple sclerosis, ocrelizumab reduced the annualised relapse rate by approximately 46% to 47% compared with subcutaneous interferon beta-1a. It also reduced the risk of confirmed 24-week disability progression by approximately 40% and suppressed active gadolinium-enhancing brain lesions on MRI scans by over 90%.
In primary progressive multiple sclerosis, the Phase III ORATORIO trial showed a 24% lower risk of 12-week confirmed disability progression and reduced brain volume loss compared with placebo. However, ocrelizumab cannot repair severed nerve fibres or reverse long-standing physical disability. Its clinical role is preventative, aimed at halting inflammatory activity and slowing neurodegeneration rather than reversing established impairment.
Ocrevus (ocrelizumab) therapy cost in Turkey and international price comparison
The cost of ocrelizumab varies substantially across borders due to pharmaceutical regulation, hospital overheads, and private insurance pricing. The figures below represent realistic, approximate private price ranges per 600 mg infusion cycle, covering the medication, hospital day-case facility, specialist neurology assessment, and nursing care.
| Country | Approximate cost range (per 6-month infusion) |
|---|---|
| Turkey | €4,500 – €9,500 |
| United Kingdom | €6,000 – €14,000 |
| United States | €15,000 – €38,000 |
| Germany | €8,000 – €16,000 |
Key factors affecting the ocrevus (ocrelizumab) therapy price include pre-infusion laboratory workups, immunoglobulin monitoring, and hospital stay arrangements. In Turkey, private hospital packages typically include neurologist consultations, infusion suite observation, and airport transfers. International coordinators assist with medical travel arrangements; learn more about how it works before scheduling your trip.
Ocrevus compared with Kesimpta, Tysabri and Rituximab
When selecting a high-efficacy disease-modifying therapy, neurologists compare ocrelizumab against other targeted options. While some neurological disorders are managed with oral agents or medication for epilepsy, autoimmune conditions like multiple sclerosis require targeted immunomodulation.
| Therapy | Administration route | Target mechanism | Typical clinical limits |
|---|---|---|---|
| Ocrevus (ocrelizumab) | Intravenous infusion every 6 months | Humanised anti-CD20 B-cell depletion | Requires hospital infusion suite; potential infusion reactions |
| Kesimpta (ofatumumab) | Subcutaneous monthly self-injection | Fully human anti-CD20 B-cell depletion | Home administration; relies on patient injection compliance |
| Tysabri (natalizumab) | Intravenous infusion every 4–6 weeks | Alpha-4 integrin blocker (prevents cell migration) | Frequent clinic visits; PML risk in JC virus-positive patients |
| Rituximab | Intravenous infusion every 6 months | Chimeric anti-CD20 antibody (often off-label) | Higher rate of anti-drug antibodies and acute infusion reactions |
Ocrelizumab offers the advantage of semi-annual clinic visits, avoiding the discipline needed for monthly home injections. Unlike natalizumab, it carries a lower association with JC virus antibody status, providing reliable disease control without monthly hospital attendance.
Who is an eligible candidate for anti-CD20 therapy?
Suitability for treatment depends on diagnostic confirmation, disease trajectory, and baseline health markers. Suitable candidates generally include:
- Adults with active relapsing-remitting multiple sclerosis demonstrating recent clinical relapses or new lesions on MRI scans.
- Patients with active secondary progressive MS exhibiting ongoing inflammatory exacerbations.
- Adults with early primary progressive multiple sclerosis who remain ambulatory and show evidence of active inflammatory lesions.
- Patients experiencing disease breakthrough or intolerable side effects on first-line injectable therapies.
Conversely, ocrelizumab is contraindicated in patients with active hepatitis B, as B-cell depletion can trigger fatal viral reactivation. It is also unsuitable for individuals with severe active systemic infections, profound hypogammaglobulinaemia, or active malignancies. Pregnant or breastfeeding women should avoid treatment, and effective contraception is advised during therapy and for several months following the final infusion.
What results and MRI changes should patients realistically expect?
Therapeutic success with ocrelizumab is evaluated through objective neurological examinations and serial neuro-imaging rather than physical appearance. Understanding realistic timelines helps prevent unrealistic expectations.
Within three to six months of starting treatment, contrast-enhanced brain and spinal MRI scans typically show marked reduction or complete cessation of new gadolinium-enhancing active lesions. Over twelve to twenty-four months, the rate of new T2 lesion formation drops sharply, and relapse frequency declines substantially. Many patients experience stabilized mobility and reduced anxiety regarding unexpected relapses.
However, ocrelizumab cannot repair existing central nervous system scar tissue. Pre-existing neurological deficits—such as established muscle weakness, spasticity, or chronic fatigue—generally remain. The primary goal of therapy is disease stabilization and the prevention of future attacks, rather than curing the condition or restoring lost function.
Ocrevus (ocrelizumab) therapy recovery and travel timeline for patients
Undergoing ocrevus (ocrelizumab) therapy in Turkey requires a structured schedule allowing for clinical evaluation, hospital infusion, and brief post-treatment recovery. Most international patients spend three to five nights in Turkey per cycle.
A typical travel and recovery itinerary includes:
- Day 1 (Consultation & tests): Meet your neurologist, undergo physical and neurological exams, and complete baseline blood panels including viral serology.
- Day 2 (Infusion day): Admission to the hospital infusion suite, administration of premedications, delivery of the intravenous infusion, and one hour of post-infusion monitoring before hotel discharge.
- Days 3–4 (Rest & follow-up): Rest at your hotel while mild fatigue or headache eases. Attend a brief clinic review to confirm stable recovery and receive fit-to-fly clearance.
- Day 5 (Return travel): Depart for home with complete medical reports, infusion logs, and doctor notes for your local healthcare provider.
Most patients resume desk work within 48 to 72 hours. Strenuous exercise should be paused for five to seven days until post-infusion tiredness resolves.
Potential side effects, infusion reactions and safety monitoring
Safety data from regulatory agencies, including the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), confirm that ocrelizumab is well tolerated under specialist supervision. Nonetheless, patients should be fully informed regarding potential risks.
Infusion-related reactions are the most common acute effect, occurring in approximately one-third of patients during the first session. Symptoms include itching, flushing, rash, headache, throat irritation, and mild fever. These reactions are typically mild and managed promptly by adjusting infusion speed or administering additional antihistamines.
Because the drug depletes B cells, patients have a higher risk of common infections, particularly upper respiratory tract infections, bronchitis, and herpes reactivation. Long-term therapy can also lead to decreased serum immunoglobulin levels (hypogammaglobulinaemia), requiring regular blood tests. Progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection, is uncommon with ocrelizumab and occurs primarily in patients with prior immunosuppressive therapy exposure.
How to choose an accredited hospital in Turkey and red flags
Selecting an accredited medical centre is vital for safety, cold-chain handling, and specialist oversight when receiving biologic therapy abroad. Ensure the facility is a licensed university or private hospital—ideally accredited by Joint Commission International (JCI)—with dedicated neuroimmunology consultants and emergency intensive care backup.
Biologics require continuous cold-chain refrigeration between 2°C and 8°C. Trustworthy hospitals provide full batch traceability and source medications solely through authorised pharmaceutical distributors. Turkish neurology departments work closely with broader medical services; review our guide to neurosurgery treatments in Turkey (hub).
Be alert to warning signs. Avoid clinics that agree to infuse ocrelizumab without examining recent MRI scans or verifying hepatitis B serology. Reject any provider promising to reverse established multiple sclerosis disability or quoting prices without a clear itemised breakdown. You can submit your recent MRI and medical history for a free quote from hospital neurology teams.
Key questions to ask your neurologist before starting treatment
Before beginning your treatment journey, consider asking the clinical team these essential questions:
- What are my baseline immunoglobulin (IgG/IgM) levels, and how often will they be rechecked?
- Have my blood panels confirmed negative results for hepatitis B and tuberculosis?
- What emergency protocols and medical staff are present in the infusion suite if an allergic reaction occurs?
- Will I receive a formal batch certificate and discharge summary in English for my home doctor?
- What infection precautions should I follow during the weeks following treatment?
- Who can I contact at the clinic if I experience delayed symptoms after returning home?
Hospitals with Neurosurgery in Turkey
Frequently asked questions
Ocrevus (ocrelizumab) therapy is a prescription humanised monoclonal antibody treatment designed for adults with relapsing forms of multiple sclerosis or primary progressive multiple sclerosis. Administered as an intravenous infusion every six months, it selectively targets and depletes CD20-positive B lymphocytes, which are immune cells directly implicated in the inflammatory cascade that damages the myelin sheath protecting nerve fibres.
Clinical trial evidence demonstrates that ocrelizumab significantly reduces the annualised relapse rate and delays confirmed disability progression in relapsing multiple sclerosis compared with traditional interferon therapies. In primary progressive multiple sclerosis, it is the first approved disease-modifying therapy shown to slow physical disability progression, although it cannot restore nerve tissue or reverse established long-standing neurological impairment.
In Turkey, an Ocrevus infusion cycle typically ranges from €4,500 to €9,500, compared with €6,000 to €14,000 in the UK and considerably higher figures in the United States. Total cost depends on pre-infusion laboratory screening, immunoglobulin profiling, medical observation, and hospital facility fees. Hospitals provide an itemised written quotation following an initial medical record review.
Before and after results are assessed through neuro-imaging and clinical exams rather than cosmetic changes. Follow-up magnetic resonance imaging typically reveals a marked reduction or complete suppression of new active gadolinium-enhancing brain and spinal lesions. Patients often experience stabilised mobility and fewer relapses, though established neurological deficits caused by prior scarring generally remain unchanged.
Recovery from the infusion itself is usually rapid. While the hospital appointment lasts three to four hours including pre-medication and monitoring, most patients experience only mild lethargy, headache, or low-grade fatigue for 24 to 48 hours. Normal sedentary work and light daily activities can generally be resumed the following day, provided no acute allergic reactions occurred.
The treatment is not painful, as it involves a standard intravenous cannula insertion into a vein in the arm. Some patients report temporary coldness at the cannula site or mild discomfort. Infusion reactions, such as an itchy throat, flushing, mild fever, or headache, are managed during administration by pre-medicating with antihistamines, paracetamol, and intravenous corticosteroids.
Each full Ocrevus infusion provides targeted B-cell depletion that lasts approximately six months. By six months, B-cell counts slowly begin to reconstitute, which is why treatment cycles are repeated semi-annually on an ongoing schedule to maintain disease suppression. Neurologists perform routine blood panels prior to each cycle to monitor immunoglobulin levels and overall immune reconstitution.
Ocrevus is approved by major regulatory bodies, including the European Medicines Agency and the US Food and Drug Administration. While generally well tolerated, it reduces immune defences, increasing susceptibility to respiratory tract infections and herpes reactivation. Long-term monitoring of immunoglobulin levels is necessary. Rare serious complications include progressive multifocal leukoencephalopathy, demanding strict ongoing clinical surveillance.
Ocrevus and Kesimpta both target CD20 B cells, but Ocrevus requires clinic-based intravenous infusions every six months, whereas Kesimpta is self-injected subcutaneously every month at home. Tysabri works differently by blocking lymphocyte migration across the blood-brain barrier and requires monthly infusions, carrying a heightened risk of progressive multifocal leukoencephalopathy in patients with positive JC virus antibodies.
Patients travelling to Turkey for Ocrevus infusion therapy typically stay between three and five nights. This timeframe allows your neurologist to conduct preliminary blood tests, check hepatitis B serology, verify recent MRI scans, administer the day-case infusion under monitored conditions, and complete a final discharge evaluation before you board your flight home.
Patient stories